辉瑞疫苗失效？以色列完全接种者感染变异毒株
由于此前在完全接种了辉瑞公司（Pfizer）新冠疫苗的成年人中出现了少量新冠病毒变异的阳性病例，以色列卫生部官员将重启室内口罩令。普遍意义上的完全接种新冠疫苗是指已经接种了两针疫苗，并且距离第二针接种已经过去了两周。
德尔塔变异毒株已经迅速成为新冠肺炎病例在印度和英国等某些国家的疫情主要来源。在美国的新病例中也占了越来越多的份额，主要集中在疫苗接种率低的州。这种突变最初在印度发现，似乎比新型冠状病毒的传播性强得多，可能对年轻人构成特别威胁。
据《华尔街日报》（Wall Street Journal）报道，以色列政府的疫情研究专家预计，以色列约90%的新病例将与德尔塔变异毒株有关。在专家检测的感染德尔塔变异毒株的病例中，约有一半发生在16岁以下未接种疫苗的儿童中。但在此次疫情中感染的成年人里，约有一半已经接种了新冠疫苗。
不过现在还不是草木皆兵的时候。早期的研究表明，在德尔塔变异毒株肆虐的英国，辉瑞疫苗在完全免疫的人群中，预防住院患者感染德尔塔变异毒株方面，有效率达到96%。据以色列政府的新冠疫情研究专家兰•巴利塞说：“在过去五天里，以色列只记录了5例新冠肺炎重症病例。当然，病例数、住院人数（以及死亡人数）这些数据都相对滞后。辉瑞疫苗在预防感染新冠肺炎德尔塔变异毒株方面是否有效，或者是否需要注射加强针来预防，这些问题还需要时间来检验。”
辉瑞公司对其疫苗对抗德尔塔变异毒株的有效性充满信心。据路透社（Reuters）报道，辉瑞公司的以色列医疗主任阿隆•拉帕波特对以色列当地电视台表示：“我们今天积累的数据源于我们在实验室进行的研究，包括来自印度德尔塔变异毒株取代英国变种成为常见病毒变种的数据，表明我们的疫苗对预防新冠肺炎的有效率约90%。”
简而言之，至少还需要几个月的时间才能够了解现有的新冠疫苗对德尔塔变异毒株起到何种作用。（财富中文网）
编译：於欣
由于此前在完全接种了辉瑞公司（Pfizer）新冠疫苗的成年人中出现了少量新冠病毒变异的阳性病例，以色列卫生部官员将重启室内口罩令。普遍意义上的完全接种新冠疫苗是指已经接种了两针疫苗，并且距离第二针接种已经过去了两周。
德尔塔变异毒株已经迅速成为新冠肺炎病例在印度和英国等某些国家的疫情主要来源。在美国的新病例中也占了越来越多的份额，主要集中在疫苗接种率低的州。这种突变最初在印度发现，似乎比新型冠状病毒的传播性强得多，可能对年轻人构成特别威胁。
据《华尔街日报》（Wall Street Journal）报道，以色列政府的疫情研究专家预计，以色列约90%的新病例将与德尔塔变异毒株有关。在专家检测的感染德尔塔变异毒株的病例中，约有一半发生在16岁以下未接种疫苗的儿童中。但在此次疫情中感染的成年人里，约有一半已经接种了新冠疫苗。
不过现在还不是草木皆兵的时候。早期的研究表明，在德尔塔变异毒株肆虐的英国，辉瑞疫苗在完全免疫的人群中，预防住院患者感染德尔塔变异毒株方面，有效率达到96%。据以色列政府的新冠疫情研究专家兰•巴利塞说：“在过去五天里，以色列只记录了5例新冠肺炎重症病例。当然，病例数、住院人数（以及死亡人数）这些数据都相对滞后。辉瑞疫苗在预防感染新冠肺炎德尔塔变异毒株方面是否有效，或者是否需要注射加强针来预防，这些问题还需要时间来检验。”
辉瑞公司对其疫苗对抗德尔塔变异毒株的有效性充满信心。据路透社（Reuters）报道，辉瑞公司的以色列医疗主任阿隆•拉帕波特对以色列当地电视台表示：“我们今天积累的数据源于我们在实验室进行的研究，包括来自印度德尔塔变异毒株取代英国变种成为常见病毒变种的数据，表明我们的疫苗对预防新冠肺炎的有效率约90%。”
简而言之，至少还需要几个月的时间才能够了解现有的新冠疫苗对德尔塔变异毒株起到何种作用。（财富中文网）
编译：於欣
Israeli health officials are returning to mask mandates at indoor facilities following a small spate of positive COVID Delta variant cases in adults who had been fully vaccinated with Pfizer's coronavirus vaccine. That is, these adults had received two doses of the vaccine, and it had been two weeks since their second dose, the generally accepted timeline for full vaccination.
The Delta variant has rapidly become the main source of new COVID cases in certain parts of the globe including India and the U.K. It also makes up an increasing share of new cases in the U.S., clustered in states with low vaccination rates. The mutation, originally identified in India, appears to be far more transmissible than the novel coronavirus and could be a particular threat to younger people.
In Israel, expert advisers to the government estimate that about 90% of new cases are linked to the Delta variant, according to the Wall Street Journal. About half of the Delta variant cases examined by experts occurred in children under the age of 16 who haven’t been vaccinated. But about half of adults who were infected in this outbreak were fully immunized with the COVID vaccine.
That doesn’t mean it’s time to panic quite yet. Early studies in the U.K., where the Delta variant is also prominent, have suggested that the Pfizer vaccine in fully immunized people is 96% effective at preventing hospitalizations for those who become infected with the Delta variant. And in the past five days, Israel has recorded only five severe cases of COVID, according to Ran Balicer, a COVID adviser to the Israeli government. Of course, illness and hospitalizations (and deaths) are all lagging indicators. It will take more time to tell just how effective Pfizer's vaccine is at preventing debilitating COVID illness in those with the Delta variant, or whether booster shots will be required to address it.
Pfizer is sounding a confident note in its vaccine's efficacy against the strain. “The data we have today, accumulating from research we are conducting at the lab and including data from those places where the Indian variant, Delta, has replaced the British variant as the common variant, point to our vaccine being very effective, around 90%, in preventing the coronavirus disease, COVID-19,” Pfizer’s Israel medical director Alon Rappaport told a local Israeli station, according to Reuters.
In short：It’s going to take at least a few more months to get a better grasp of the relationship between available COVID vaccines and the Delta variant.
